The Effect of Vitamin C on Growth Hormone Secretion
Withdrawn before enrolling · Phase 2 · Has a placebo group
Conditions studied: Obese, Disorder of Vitamin C, Growth Hormone Secretion Abnormality
In brief
Obesity is associated with reduced growth hormone (GH) secretion. GH secretion is regulated by nutritional stimuli including fasting, insulin, glucose and free fatty acids. However, the role of micronutrients, such as vitamins, on GH secretion has not been investigated in much detail. Vitamin C levels are also reduced in obesity, and the investigators recently demonstrated a possible role for dietary vitamin C intake in the regulation of GH secretion in two preliminary retrospective studies. The investigators therefore propose a more detailed prospective physiological study to examine the effects of increasing dietary vitamin C intake on GH secretion in a physiologic, intervention study. The investigators hypothesize that increasing vitamin C concentrations in obese subjects with sub-optimal plasma vitamin C levels and reduced GH secretion will increase GH secretion.
Key facts
- Study ID
- NCT01537094
- Run by
- Massachusetts General Hospital
- People needed
- 0
- Starts
- 2013-12-01
- Expected to finish
- 2013-12-01
- Last updated by the study team
- 2013-12-13
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Men and women age 18-60
- BMI ≥ 30 kg/m2
- Waist circumference ≥ 102 cm in men and ≥ 88 cm in women
- Plasma vitamin C concentration ≤ 23 µmol/l
- Peak stimulated GH ≤ 4.2 µg/l upon GHRH-arginine stimulation test
You may not qualify if…
- History of hypopituitarism, pituitary surgery, pituitary/brain radiation, recent traumatic brain injury or any other condition known to affect the GH axis.
- History of severe chronic illness including anemia, chronic kidney disease, liver disease, oxygen dependent COPD or HIV
- Subjects on testosterone, glucocorticoids, anabolic steroids, GHRH, GH or IGF-1 within 3 months of enrollment
- Use of dietary supplements including vitamin C or once daily multi-vitamins
- Subjects with Hgb < 912 g/dL, SGOT > 2.5x upper limit of normal or Creatinine > 1.5 mg/dL
- Subjects with poorly controlled diabetes, defined as HbA1c > 8%.
- Changes in lipid lowering or anti-hypertensive regimen within 3months of screening
- Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit
- Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient.
Where it is running
- Massachusetts General Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.